Chondrodysplasia Punctata 2, X-Linked
Summary
Clinical characteristics.
The findings in X-linked chondrodysplasia punctata 2 (CDPX2) range from fetal demise with multiple malformations and severe growth retardation to much milder manifestations, including females with no recognizable physical abnormalities. At least 95% of liveborn individuals with CDPX2 are female. Characteristic features include growth deficiency; distinctive craniofacial appearance; chondrodysplasia punctata (stippling of the epiphyses of the long bones, vertebrae, trachea, and distal ends of the ribs); often asymmetric rhizomelic shortening of limbs; scoliosis; linear or blotchy scaling ichthyosis in the newborn; later appearance of linear or whorled atrophic patches involving hair follicles (follicular atrophoderma); coarse hair with scarring alopecia; and cataracts.
Diagnosis/testing.
The diagnosis of CDPX2 is established in a female proband with: typical clinical findings, increased concentration of 8(9)-cholestenol and 8-dehydrocholesterol in plasma, scales from skin lesions, or cultured lymphoblasts or fibroblasts; and/or a heterozygous pathogenic variant in EBP identified by molecular genetic testing.
The diagnosis of CDPX2 is established in a male proband with: typical clinical findings, increased concentration of 8(9)-cholestenol and 8-dehydrocholesterol in plasma, scales from skin lesions, or cultured lymphoblasts or fibroblasts; and/or a hemizygous pathogenic variant in EBP identified by molecular genetic testing.
Management.
Treatment of manifestations: Treatment is symptomatic and individualized. For individuals with typical CDPX2 diagnosed in the newborn period, the following are appropriate: orthopedic management of leg length discrepancy; frequent assessment of kyphoscoliosis; management of respiratory compromise as per pulmonologist; dermatologic management with emollients and keratolytics; sun protection; cataract extraction and correction of vision; standard interventions for hearing loss and hydronephrosis; family support.
Surveillance: Regular orthopedic evaluations to monitor kyphoscoliosis, joint problems, and any leg length discrepancy; follow up with a dermatologist; regular follow up of ophthalmologic abnormalities; audiology evaluations as indicated; monitor hydronephrosis if present.
Agents/circumstances to avoid: Prolonged sun exposure for individuals with ichthyosis, who are at risk of dehydration secondary to overheating. Use of emollients (which are oil based) and direct sun exposure can lead to sunburn.
Genetic counseling.
CDPX2 is inherited in an X-linked manner with early gestational male lethality. Women with an EBP germline pathogenic variant have a 50% chance of transmitting the pathogenic variant to each child: EBP pathogenic variants in sons are usually lethal; daughters will have a range of possible phenotypic expression. When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low but greater than that of the general population. If the pathogenic variant cannot be detected in the DNA extracted from the leukocytes of either parent of the proband, three possible explanations are germline mosaicism, somatic mosaicism, or a de novo pathogenic variant in the proband. Prenatal diagnosis for pregnancies at increased risk is possible if the family-specific pathogenic variant is known.
Diagnosis
X-linked chondrodysplasia punctata 2 (CDPX2) is a skeletal dysplasia that also affects the skin and eyes. Specific diagnostic criteria for CDPX2 have not been published. Classic CDPX2 occurs almost exclusively in females. There are reports of affected males with an XXY karyotype [Sutphen et al 1995] or with somatic mosaicism [Aughton et al 2003, Tan et al 2010] who have clinical manifestations similar to affected females.
Suggestive Findings
CDPX2 should be suspected in an individual with the following clinical findings:
- Growth deficiency/short stature
- Craniofacial findings
- Frontal bossing
- Depressed nasal bridge
- Sparse eyebrows and lashes, often asymmetric
- Skeletal abnormality
- Stippling (chondrodysplasia punctata) involving the epiphyses of the long bones and vertebrae, the trachea, and distal ends of the ribs seen on x-ray. The presence of stippling is age dependent and cannot be seen once normal epiphyseal ossification progresses during childhood (see Figure 1).
- Rhizomelic (i.e., proximal) shortening of limbs that is often asymmetric, but occasionally symmetric
- Scoliosis, occasionally congenital
- Postaxial polydactyly (uncommon)
- Abnormality of skin, hair, and nails
- Scaling ichthyosis on an erythematous base arranged in a linear or blotchy pattern in the newborn period (following lines of Blaschko) that usually resolves in the first months of life and may be followed by linear or whorled atrophic patches involving hair follicles (follicular atrophoderma) (see Figure 2) and/or pigmentary abnormalities
- Coarse scalp hair with scarring alopecia (see Figure 3)
- Occasional flattened or split nails
Note: Teeth are normal. - Ocular anomaly
- Cataracts often congenital, asymmetric, and/or sectorial
- Microphthalmia and/or microcornea
Figure 1.
Figure 2
Figure 3.
Establishing the Diagnosis
Female proband. The diagnosis of CDPX2 is established in a female proband with typical clinical findings, characteristic results on biochemical testing (see Table 1), and/or a heterozygous pathogenic variant in EBP identified by molecular genetic testing (see Table 2).
Male proband. The diagnosis of CDPX2 is established in a male proband (with a 46,XY karyotype) with the typical clinical findings, characteristic results on biochemical testing (see Table 1), and/or a mosaic hemizygous pathogenic variant in EBP identified by molecular genetic testing (see Table 2).
Note: Males with non-mosaic hypomorphic EBP pathogenic variants have MEND (male EBP disorder with neurologic defects) syndrome, a clinically distinct phenotype comprising neurologic and structural malformations without chondrodysplasia punctata [Arnold et al 2012].
Biochemical testing. Sterol analysis of plasma, scales from skin lesions, or cultured lymphoblasts or fibroblasts can be used for diagnosis. Increased concentrations of 8(9)-cholestenol and 8-dehydrocholesterol are essentially diagnostic of CDPX2 [Kelley et al 1999] (Table 1); however, individuals with molecularly confirmed CDPX2 with normal biochemical profiles have been reported [Whittock et al 2003]. There is no correlation between the levels of plasma 8(9)-cholestenol and 8-dehydrocholesterol and mutational subgroups or specific phenotypic traits [Has et al 2002]. In affected males, biochemical testing will not be of use in differentiating CDPX2 from MEND syndrome (see Genetically Related Disorders).
Table 1.
Analyte | CDPX2 | Normal |
---|---|---|
Plasma 8(9)-cholestenol | 0.18-186 μg/mL | <0.01 μg/mL (for neonates age 1-2 days) |
Plasma 8-dehydrocholesterol | <0.01-138 μg/mL | <0.01 μg/mL (for neonates age 1-2 days) |
Data from 105 females with presumed CDPX2 [R Kelley, personal communication]
Histologic examination of skin biopsies of individuals with CDPX2 show dilated ostial hyperkeratosis of the hair follicle with keratin calcium deposits [Leclerc-Mercier et al 2015]. These findings are relatively specific for CDPX2 and have been reported in only a couple of other conditions. Skin biopsy from the affected area may therefore be a useful diagnostic adjunct in individuals with a milder presentation.
Molecular Genetic Testing
In centers where it is readily available, molecular genetic testing should be considered first. Biochemical testing can be used to support a diagnosis in individuals with inconclusive molecular variants.
Molecular genetic testing approaches can include a combination of gene-targeted testing (single-gene testing, multigene panel) and comprehensive genomic testing (exome sequencing, genome sequencing) depending on the phenotype.
Gene-targeted testing requires that the clinician determine which gene(s) are likely involved, whereas genomic testing does not. Because the phenotype of CDPX2 is broad, individuals with the distinctive findings described in Suggestive Findings are likely to be diagnosed using gene-targeted testing (see Option 1), whereas male probands or those in whom the diagnosis of CDPX2 has not been considered due to atypical findings are more likely to be diagnosed using genomic testing (see Option 2).
Option 1. When the phenotypic and laboratory findings suggest the diagnosis of CDPX2 molecular genetic testing approaches can include single-gene testing or use of a multigene panel:
- Single-gene testing. Perform sequence analysis of EBP to detect small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected.
- A multigene panel that includes EBP and other genes of interest (see Differential Diagnosis) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.
Option 2. When the diagnosis of CDPX2 is not considered because an individual has atypical phenotypic features, comprehensive genomic testing (which does not require the clinician to determine which gene[s] are likely involved) is the best option. Exome sequencing is the most commonly used genomic testing method; genome sequencing is also possible.
For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.
Table 2.
Gene 1 | Method | Proportion of Probands with a Pathogenic Variant 2 Detectable by Method |
---|---|---|
EBP | Sequence analysis 3, 4 | ~100% 5 |
Gene-targeted deletion/duplication analysis 6 | None reported 5 |
- 1.
See Table A. Genes and Databases for chromosome locus and protein.
- 2.
See Molecular Genetics for information on allelic variants detected in this gene.
- 3.
Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.
- 4.
Lack of amplification by PCR prior to sequence analysis can suggest a putative (multi)exon or whole-gene deletion on the X chromosome in affected males; confirmation requires additional testing by gene-targeted deletion/duplication analysis.
- 5.
Review of approximately 80 pathogenic variants in all available published case literature, ClinVar [Landrum et al 2014], and HGMD [Stenson et al 2017] did not identify large intragenic deletions or duplications as a cause of CDPX2 [Author, personal observation].
- 6.
Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.
Clinical Characteristics
Clinical Description
Variability in females. At least 95% of individuals with X-linked chondrodysplasia punctata 2 (CDPX2) are female. The clinical phenotypes in heterozygous females are highly variable and depend on the pattern of X-chromosome inactivation in relevant tissues (i.e., percentage of active X chromosomes with the pathogenic variant) and other possible modifying factors. Phenotypes range from fetal demise with multiple malformations and severe growth retardation to much milder manifestations, such as adults with only cutaneous features, short stature, or no recognizable physical abnormalities. Severity in females varies greatly within families and among individuals with the same pathogenic variant, as would be expected for a pathogenic process determined, in part, by the random process of X-chromosome inactivation.
Phenotypes in males. Although CDPX2 was for many years presumed to be lethal in males, a small number of affected males have been reported. Sutphen et al [1995] described a male with CDPX2 and a 47,XXY karyotype. Males with mosaic EBP variants have also been reported [Aughton et al 2003, Tan et al 2010, Arnold et al 2012, Pacault et al 2018, Honigman et al 2019, Horinouchi et al 2019] with allele fractions ranging from 20% to 75% detected in blood and skin [Pacault et al 2018, Honigman et al 2019, Horinouchi et al 2019]. The clinical characteristics of males with mosaic EBP pathogenic variants are well within the marked variability described in affected females.
Clinical Findings Associated with Classic CDPX2
Growth deficiency/short stature. The most common nonspecific skeletal manifestation in individuals with CDPX2 is short stature [Cañueto et al 2012]. Reported heights range from the 10th-25th percentile to 6 SD below the mean.
Craniofacial appearance. The face and head are often asymmetric. Most individuals with CDPX2 have a depressed bridge and frontal bossing. Other distinctive features include downslanting palpebral fissures, hypertelorism, low-set ears, and high-arched palate [Happle 1979, Herman 2000].
Skeletal. Stippling (chondrodysplasia punctata) most commonly involving the epiphyses of the long bones, but also the ribs, vertebrae, and tracheal cartilage is seen on radiographs in almost 100% of symptomatic infants; however, this could reflect ascertainment bias. Epiphyseal stippling can be detected on prenatal ultrasound from the second trimester [Lefebvre et al 2015] and is present in infancy and variably in childhood (during endochondral bone formation). It is usually radiologically absent in adults with CDPX2.
Approximately 90% of individuals have asymmetric (or occasionally symmetric) shortening of limbs involving mostly the femur, humerus, and other tubular bones [Happle 1979].
Moderate-to-severe kyphoscoliosis is common and can present in infancy or early childhood. Lung disease may develop secondary to progressive kyphoscoliosis and can lead to death [Sutphen et al 1995]. Spinal deformities can progress rapidly; in addition, progressive deformity following surgical vertebral fusion is common [Mason et al 2002]. Contractures, other joint abnormalities, dislocated patella and hips, and postaxial polydactyly have also been reported [Happle 1979, Has et al 2000, Herman 2000, Cañueto et al 2012, Cardoso et al 2014].
Skin, hair, and nails. The skin is involved in more than 95% of individuals of CDPX2 [Cañueto et al 2012]. Scaling ichthyosis on an erythematous base is present in newborns in a linear or blotchy pattern. The ichthyosis follows the lines of Blaschko and has a feather-like edge, but total scaling erythroderma also occurs. As the rash fades in the first weeks or months of life, it leaves a linear or whorled pattern of atrophoderma predominantly near hair follicles where scales had been located. Some individuals also have ichthyosis and/or pigmentary abnormalities that persist into childhood and adulthood.
Hair findings include scarring alopecia in patches, sparse eyelashes and eyebrows, and coarse, lusterless hair.
Minor nail findings include flattening and splitting of the nail plates [Happle 1979, Herman 2000, Hoang et al 2004].
Ocular. Approximately two thirds of individuals have cataracts at birth or develop them early in life. Cataracts are usually unilateral, asymmetric, and/or sectorial [Happle 1979, Happle 1981, Herman et al 2002]. Other eye findings include microphthalmia and/or microcornea.
Neurologic. Intelligence is typically normal in affected individuals unless a CNS malformation is present. Rarely reported neurologic abnormalities in males include posterior fossa arachnoid cysts and medullary atrophy secondary to atlas hypoplasia [Horinouchi et al 2019].
Ear anomalies and hearing. Rarely, dysplastic auricles and sensorineural hearing loss have been reported in affected individuals [Happle 1979, Herman et al 2002, Ozyurt et al 2015].
Other findings
- Individuals with CDPX2 may also have bilateral or unilateral clubfoot [Herman et al 2002].
- Hydronephrosis has been seen in several affected females [Herman et al 2002].
- Hypoglycemia in the neonatal period has been reported [Cañueto et al 2012, Horinouchi et al 2019].
Mortality. Typically, life expectancy is normal in individuals with CDPX2, although severe scoliosis may compromise heart and lung function and negatively affect life expectancy.
Genotype-Phenotype Correlations
Null EBP variants are associated with a severe CDPX2 phenotype in females and result in intrauterine lethality in males (except in a mosaic state).
Hypomorphic hemizygous EBP variants are associated with a milder MEND phenotype in males (see Genetically Related Disorders) [Barboza-Cerda et al 2014, Barboza-Cerda et al 2019].
Penetrance
A few clinically unaffected females with molecularly confirmed CDPX2 have been reported [Herman et al 2002, Shirahama et al 2003, Hellenbroich et al 2007]. However, these females were ascertained from segregation testing, and phenotyping may not have been as comprehensive as in the proband. Some women have been so mildly affected that they were identified only after having had a child with more severe features in whom CDPX2 was diagnosed. Although these adult women have subtle findings, their findings are sufficient to consider them affected.
Nomenclature
CDPX2 has also been referred to as:
- Conradi-Hünermann syndrome, named after Conradi [1914] and Hünermann [1931], who described the first persons with this disorder;
- Happle syndrome, named after Rudolph Happle [Happle 1979, Happle 1981], who contributed greatly to characterization of the phenotype and delineation of the X-linked mode of inheritance and possible etiologies of the syndrome [Traupe 1999, Sheffield 2001];
- Conradi-Hünermann-Happle syndrome, which recognizes all three individuals who helped to define this disorder.
Prevalence
Prevalence is unknown and incidence is estimated at 1:100,000 to 1:200,000 births.
Differential Diagnosis
Several disorders demonstrate features similar to those of X-linked chondrodysplasia punctata 2 (CDPX2) and/or manifest stippling on radiographs and various combinations of limb asymmetry, short stature, intellectual disability, cataracts, and skin changes. The key radiologic finding of chondrodysplasia punctata occurs in various metabolic disorders, skeletal dysplasias, chromosome abnormalities, and teratogenic exposures.
Genetic Disorders
Table 3.
Differential Diagnosis Disorder | Gene(s) | MOI | Features of the Differential Diagnosis Disorder | |
---|---|---|---|---|
Overlapping w/CDPX2 | Distinguishing from CDPX2 | |||
Skeletal dysplasia w/radiographic evidence of CDP 1 | ||||
Chondrodysplasia punctata 1, X-linked (CDPX1) | ARSL (ARSE) 2 | XL | Affected males have short stature & short limbs |
|
CHILD syndrome (congenital hemidysplasia, ichthyosis, limb defects) (see NSDHL Disorders) | NSDHL 3 | XL |
|
|
Keutel syndrome (OMIM 245150) | MGP | AR | CDP in addition to brachytelephalangy | Peripheral pulmonary stenosis, brachytelephalangia, & hearing impairment are key features of Keutel syndrome. |
Greenberg dysplasia (OMIM 215140) | LBR | AR | Skeletal abnormalities incl CDP, rhizomelia, polydactyly, & vertebral anomalies |
|
Rhizomelic chondrodysplasia punctata type 1 (RCDP1) | PEX7 | AR |
|
|
RCDP2 (OMIM 222765) | GNPAT | AR | ||
RCDP3 (OMIM 600121) | AGPS | AR | ||
RCDP5 (OMIM 616716) | PEX5 | AR | ||
Disorders of post-squalene cholesterol biosynthesis | ||||
Smith-Lemli-Opitz syndrome | DHCR7 | AR | Skeletal abnormalities incl rhizomelia & polydactyly |
|
Antley-Bixler syndrome (see Cytochrome P450 Oxidoreductase Deficiency) | POR | AR | Skeletal abnormalities incl rhizomelia & scoliosis |
|
Desmosterolosis (OMIM 602398) | DHCR24 | AR | Skeletal abnormalities incl rhizomelia, joint contractures, & poor growth |
|
Lathosterolosis (OMIM 607330) | SC5D | AR | Skeletal abnormalities incl rhizomelia, postaxial polydactyly & spinal abnormalities | No CDP or skeletal asymmetry |
CK (see NSDHL Disorders) | NSDHL | XL | Mild skeletal abnormalities incl scoliosis/kyphosis |
|
Sterol-C4-methyloxidase-like deficiency (OMIM 616834) | MSMO1 (SC4MOL) | AR | Short stature, generalized ichthyosiform dermatitis, & cataracts reported | Broader phenotype incl ID, immune dysfunction, & failure to thrive |
Peroxisome biogenesis disorders | ||||
Zellweger spectrum disorder | PEX1 PEX2 PEX3 PEX5 PEX6 PEX10 PEX11B PEX12 PEX13 PEX14 PEX16 PEX19 PEX26 | AR | CDP of the patella & long bones | Broader phenotype incl congenital malformations, seizures, & liver disease of variable severity |
AR = autosomal recessive; CDP = chondrodysplasia punctata; CDPX2 = chondrodysplasia punctata 2, X-linked; DD = developmental delay; ID = intellectual disability; MOI = mode of inheritance; XL = X-linked
- 1.
Classification of differential diagnoses is presented according to the most recent Nosology and Classification of Skeletal Disorders [Mortier et al 2019].
- 2.
Contiguous gene deletions involving ARSL and other genes in this region result in more complex phenotypes, including, variously, additional findings of ichthyosis, anosmia, hypogonadism, short stature, and corneal opacities.
- 3.
CHILD syndrome is caused by pathogenic variants in NSDHL, which encodes a cholesterol biosynthetic 4-methylsterol dehydrogenase [König et al 2000]. The enzyme, part of a 4-methylsterol demethylase complex, occurs one step proximal to the EBP sterol isomerase.
- 4.
Individuals with CHILD syndrome have increased levels of 4-methyl- and carboxysterols in cultured lymphoblasts, but only occasionally in plasma, whereas those with CDPX2 have increased levels of 8(9)-cholestenol and 8-dehydrocholeterol. In cultured lymphoblasts, both disorders manifest a paradoxic increase in the distal sterol metabolite lathosterol, including hemizygous males with an EBP pathogenic variant. The embryologic cause of the CHILD phenotype, common in NSDHL deficiency and rare in EBP deficiency, is unknown. Interestingly, fibroblasts cultured from normal skin from both the hemidysplastic and normal sides of the body can manifest the classic abnormal sterol profile.
- 5.
See Genetically Related Disorders.
Chondrodysplasia punctata, tibia-metacarpal (OMIM 118651) and humero-metacarpal types are inherited in an autosomal dominant manner. The associated genes are unknown. Affected individuals have short limbs due primarily to shortening of the tibiae/humeri, metacarpals, and phalanges. Vertebral anomalies are also found. CDP is usually confined to the sacral, carpal, and tarsal areas. No skin or eye changes are present; intellect and life expectancy is normal [Savarirayan et al 2004].
Astley-Kendall dysplasia has been postulated to be an allelic disorder of Greenberg dysplasia [Author, personal communication]. Ossification defects of the cranial vault, spine, and long bones result in shortened and dysplastic long bones and vertebrae in affected individuals.
Teratogen Exposures
Warfarin embryopathy and other vitamin K deficiencies (including vitamin K epoxide reductase deficiency) are phenotypically similar to X-linked chondrodysplasia punctata 1 with especially severe hypoplasia of the nasal bone ("Binder anomaly"), distal phalangeal abnormalities, and punctata of the axial skeleton.
Maternal autoimmune disease (systemic lupus erythematosus [SLE], mixed connective tissue disease and scleroderma) can cause CDP with rhizomelic limb shortening.
Management
No published guidelines exist to establish the extent of disease or proper management in an individual with X-linked chondrodysplasia punctata